The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By

Portfolio of GlaxoSmithKline plc consumer and OTC brands

Advised GlaxoSmithKline plc, a leading British pharmaceutical company, on the disposal of a portfolio of consumer and OTC brands to Omega Pharma NV, a subsidiary of Perrigo Company plc

Unfors Raysafe AB

Advised the Sixth Swedish National Pension Fund on the sale of Unfors Raysafe AB, a provider of easy-to-use products that help to reduce unnecessary radiation exposure, to Fluke Biomedical Corp., a subsidiary of Danaher Corp. that manufactures biomedical test and simulation products

Warner Chilcott, plc

Advised Actavis, Inc., a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, branded and biosimilar products on its acquisition of Warner Chilcott plc

Maxinutrition Group Holdings Limited

Advised GlaxoSmithKline Plc, the UK listed international pharmaceutical and consumer company, on its acquisition of Maxinutrition Group Holdings Limited, a UK based sports nutrition business, from Darwin Private Equity

Healthcare Australia

Advised CHAMP Private Equity on the sale of Healthcare Australia, a leading provider of nursing agency staff to public and private health institutions in Australia, to Healthcare Locums, a healthcare recruitment agency based in the UK

Biotage (Biosystems division)

Advised Biotage AB (OMX: BIOT), a global biotechnology company, on its strategic review resulting in the disposal of its Biosystems division which offers systems for genetic analysis mainly for use in clinical research